ROC CURVE - Diagnostic performances and therapeutic impact of the Unyvero Implant and Tissue Infection multiplex PCR in periprosthetic joint infections
posted on 2023-08-04, 15:32authored byClaire Richarme, Patricia Pavese, Brice Rubens-Duval, Olivier Seurat, Marion Le Marechal, Sandrine Boisset
<p> </p>
<p><strong>Aim: </strong>We evaluated the diagnostic performances of Unyvero Implant and Tissue Infection multiplex PCR (mPCR) (Curetis) and the clinical impact of this PCR on therapeutic decisions. <strong>Materials & methods:</strong>AmPCR was performed on 33 joint fluids in addition to standard culture. A group of experts analyzed <em>a posteriori </em>the impact of the mPCR in the patient management. <strong>Results: </strong>The rate of concordance with culture was 74% (20<strong>/</strong>27). The sensitivity of the PCR was 59% and the specificity 90%. Clinicians would have started an appropriate treatment sooner for six patients (from 2 to 22 days earlier). <strong>Conclusion: </strong>The PCR would improve the management of 22% of the patients. For other patients, mPCR results have to be completed with the culture. </p>